A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers

c-Met is a well-characterized oncogene that is associated with poor prognosis in many solid tumor types. While responses to c-Met inhibitors have been observed in clinical trials, activity appears to be limited to those with MET gene amplifications or mutations. We developed a c-Met targeted antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Ryo, Blot, Vincent, Wong, Eley, Stewart, Christine, Lieuw, Vincent, Richardson, Robyn, Banah, Ammar, Villicana, Jose, Timmer, Anjuli, Coronella, Julia, Newman, Roland, Gymnopoulos, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515515/
https://www.ncbi.nlm.nih.gov/pubmed/32192391
http://dx.doi.org/10.1080/15384047.2020.1737490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515515/
https://www.ncbi.nlm.nih.gov/pubmed/32192391
http://dx.doi.org/10.1080/15384047.2020.1737490

Ejemplares similares